197 related articles for article (PubMed ID: 20861678)
1. Pricing of new vaccines.
Lee BY; McGlone SM
Hum Vaccin; 2010 Aug; 6(8):619-26. PubMed ID: 20861678
[TBL] [Abstract][Full Text] [Related]
2. Glovax's perspective: opportunities and approaches to vaccine business in Asia.
Shin SH
Dev Biol (Basel); 2002; 110():31-4. PubMed ID: 12477304
[TBL] [Abstract][Full Text] [Related]
3. Analytics for vaccine economics and pricing: insights and observations.
Robbins MJ; Jacobson SH
Expert Rev Vaccines; 2015 Apr; 14(4):605-16. PubMed ID: 25435003
[TBL] [Abstract][Full Text] [Related]
4. Vaccine pricing: how can we get it right?
Jacobson SH
Expert Rev Vaccines; 2012 Oct; 11(10):1163-5. PubMed ID: 23176647
[No Abstract] [Full Text] [Related]
5. Tiered Pricing and Alternative Mechanisms for Equitative Access to Vaccines in Latin America: A Narrative Review of the Literature.
Arango-Luque A; Yucumá D; Castañeda CE; Espin J; Becerra-Posada F
Value Health Reg Issues; 2024 Jul; 42():100981. PubMed ID: 38677063
[TBL] [Abstract][Full Text] [Related]
6. Pricing strategy and tactics in the new hospital marketplace.
Pointer DD; Zwanziger J
Hosp Health Serv Adm; 1986; 31(6):5-18. PubMed ID: 10279762
[TBL] [Abstract][Full Text] [Related]
7. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles.
Lee BY; Burke DS
Vaccine; 2010 Apr; 28(16):2806-9. PubMed ID: 19782109
[TBL] [Abstract][Full Text] [Related]
8. Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic.
Neumann PJ; Cohen JT; Kim DD; Ollendorf DA
Health Aff (Millwood); 2021 Jan; 40(1):53-61. PubMed ID: 33211534
[TBL] [Abstract][Full Text] [Related]
9. Setting prices for new vaccines (in advance).
McGuire TG
Int J Health Care Finance Econ; 2003 Sep; 3(3):207-24. PubMed ID: 14626000
[TBL] [Abstract][Full Text] [Related]
10. Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020.
Gandhi G; Lydon P; Cornejo S; Brenzel L; Wrobel S; Chang H
Vaccine; 2013 Apr; 31 Suppl 2():B137-48. PubMed ID: 23598475
[TBL] [Abstract][Full Text] [Related]
11. Tiered pricing of vaccines: a win-win-win situation, not a subsidy.
Plahte J
Lancet Infect Dis; 2005 Jan; 5(1):58-63. PubMed ID: 15620562
[TBL] [Abstract][Full Text] [Related]
12. Availability of quality vaccines: policies of a non-government organization.
Poore P
Vaccine; 1992; 10(13):958-60. PubMed ID: 1471421
[TBL] [Abstract][Full Text] [Related]
13. Public support in the United States for global equity in vaccine pricing.
Chan Y; Datt G; Islam A; Rai B; Wang LC
Sci Rep; 2022 May; 12(1):8960. PubMed ID: 35624169
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of South Africa's public-private partnership for the localisation of vaccine research, manufacture and distribution.
Walwyn DR; Nkolele AT
Health Res Policy Syst; 2018 Mar; 16(1):30. PubMed ID: 29587777
[TBL] [Abstract][Full Text] [Related]
15. [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
Barth J; Hammerschmidt T; Vollmar J; Bierbaum M; Schöffski O
Gesundheitswesen; 2014 Apr; 76(4):e7-e13. PubMed ID: 24081570
[TBL] [Abstract][Full Text] [Related]
16. Pricing medicines: theory and practice, challenges and opportunities.
Gregson N; Sparrowhawk K; Mauskopf J; Paul J
Nat Rev Drug Discov; 2005 Feb; 4(2):121-30. PubMed ID: 15688076
[TBL] [Abstract][Full Text] [Related]
17. Vaccine purchasing groups in the United States: An overview of their policies and practices.
Cowan AE; Clark SJ; Gordon JL; Bok K; Shen AK
Vaccine; 2016 Sep; 34(42):5060-5065. PubMed ID: 27614782
[TBL] [Abstract][Full Text] [Related]
18. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
Mendoza RL
J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
[TBL] [Abstract][Full Text] [Related]
19. Demand forecasting for preventive AIDS vaccines: economic and policy dimensions.
Hecht R; Gandhi G
Pharmacoeconomics; 2008; 26(8):679-97. PubMed ID: 18620461
[TBL] [Abstract][Full Text] [Related]
20. Time Series Analysis on the Impact of Generic Substitution and Reference Pricing on Antipsychotic Costs in Finland.
Koskinen H; Mikkola H; Saastamoinen LK; Ahola E; Martikainen JE
Value Health; 2015 Dec; 18(8):1105-12. PubMed ID: 26686797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
